http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing
-
Mineralys presents lorundrostat data for hypertension patients with kidney disease
-
Mineralys presents positive chronic kidney disease data for lorundrostat
-
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiova
-
Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference
-
Mineralys Therapeutics to present lorundrostat data at European meeting
-
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
-
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
-
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026
-
Mineralys Therapeutics names Jeffrey Munsie as chief legal officer
-
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
-
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
-
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
-
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026
-
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Mineralys Therapeutics Provides Corporate Update and Announces Participation in Upcoming LifeSci Partners Corporate Access Event in January 2026
-
JAMA recognizes Mineralys' hypertension trial as top 2025 research
-
Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup
-
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
-
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
-
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
-
Mineralys Therapeutics to Announce Third Quarter 2025 Financial Results and Host Conference Call on Monday, November 10, 2025
-
Mineralys to present Phase 2 CKD trial data at ASN Kidney Week 2025
-
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025
-
Mineralys completes enrollment in sleep apnea drug trial
-
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension
-
Mineralys shows lorundrostat effective across diverse hypertension groups
-
Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
-
Mineralys Therapeutics launches $175 million public stock offering
-
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
-
Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025
-
Mineralys Therapeutics (MLYS) announces positive results from Phase 3 Launch-HTN trial
-
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
-
Mineralys Therapeutics (MLYS) Announces Positive Topline Results from Phase 2 Explore-CKD Trial
-
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
-
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension
-
Mineralys Therapeutics (MLYS) Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
-
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
-
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
-
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
-
Mineralys Therapeutics (MLYS) announces publication of phase 2 Advance-HTN results
-
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
-
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual
